



Hematopoietic Stem Cell Transplantation in the Personalized Medicine Era

Guest Editors:

Prof. Dr. Michael Uhlin

1. Department of Clintec,
Karolinska Institutet, SE-141 86
Stockholm, Sweden
2. Department of Clinical
Immunology and Transfusion
Medicine, Karolinska University
Hospital, SE-141 86 Stockholm,
Sweden

Prof. Dr. Moustapha Hassan

Division of Experimental Cancer
Medicine (ECM), Department of
Laboratory Medicine, Karolinska
Institutet, SE-141 86 Stockholm,
Sweden

Deadline for manuscript
submissions:

closed (31 December 2021)

Message from the Guest Editors

Allogeneic hematopoietic stem cell transplantation (HSCT) can be curative for patients with severe hematological malignancies. Though the treatment modality has improved drastically over the last decade, e.g. tumor resistance, relapse, infections and Graft-versus-host-disease (GVHD) are still common challenges for these patients. The era of personalized medicine has dramatically changed the game plan for several diseases in the last decade including patients that undergo HSCT. Current advances in technology have provided scientists and physicians with a huge toolbox with possible instruments in order to improve the clinical outcome of these patients. This Special Issue of the *Journal of Personalized Medicine* aims to highlight the knowledge and illustrate some of the findings in HSCT. It will among other things include studies on the impact of donor characteristics and how pre-transplantation factors impact clinical outcome. It will also give examples of studies on the use of biomarkers to predict and govern clinical practise. Some examples will also illustrate how the use of tailor-made chemotherapy can be beneficial in patient care in a personalized setting.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)